X4 Pharmaceuticals, Inc. (XFOR)
Free
No email, no account, no signup.
Pulling latest news for X4 Pharmaceuticals, Inc.…
Bull
Bear
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99.
Get the deep 4-model report – $4.99
Order analysis – $4.99
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Exchange
NASDAQ
Type
Biotech
Sector
Biotech / rare hematology diseases
Market Cap
$398M
We're already tracking X4 Pharmaceuticals, Inc. — here are the latest events we've registered
Recent News
- On May 6, 2026, the company reported Q1 2026 revenue of $2.7 million, primarily from U.S. sales of XOLREMDI. The European Commission granted marketing authorization for XOLREMDI to treat WHIM syndrome in the EU on April 29, 2026. X4 remains on track to complete enrollment for its pivotal Phase 3 4WARD trial in chronic neutropenia by the end of the third quarter of 2026.
Want to know how this news affects X4 Pharmaceuticals, Inc.? Order the analysis.
Order analysis – $4.99
What you get
A complete express analysis — not just a signal. Delivered as a webpage in your account.
- Signal: BUY / HOLD / SELL — with clear reasoning
- Sentiment score 1–10 based on news, reports, and market data
- Risk score 1–10 (dilution, jurisdiction, execution)
- Bull case: 3–5 specific points with evidence (e.g. "Oversold after panic-reaction to security news, opening a technical bounce setup")
- Bear case: 3–5 specific risks (e.g. "Extreme uncertainty around the security situation in Sinaloa after tragic events")
- Upcoming catalysts with dates
- Assessment of dilution risk
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of X4 Pharmaceuticals, Inc. will be delivered in the same format.
Not satisfied? Get your money back within 7 days — no questions asked.
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.